| Literature DB >> 33269114 |
Yeisson Galvis-Pérez1, Catalina Marín-Echeverri1, Claudia Patricia Franco Escobar1, Juan C Aristizábal2, Maria-Luz Fernández3, Jacqueline Barona-Acevedo1.
Abstract
The metabolic syndrome (MS) is a constellation of related factors that increases the risk of developing cardiovascular diseases. Vaccinium meridionale Swartz contains polyphenols that could modulate some components of MS. Epidemiological and intervention studies have shown differences between men and women in MS components and antioxidant capacity. The objective of this study is to compare between men and women with MS the effects of agraz consumption on insulin resistance, antioxidant capacity, and markers of oxidation and inflammation. Men and women diagnosed with MS according to the Adult Treatment Panel III criteria were recruited in a double-blind, crossover study of 12 weeks. Participants were assigned to consume agraz nectar or placebo over 4 weeks. After 4 weeks of washout, they were switched to the alternative treatment. At the end of each period, the components of the MS, insulin resistance, antioxidant capacity, and some oxidative (oxidized low-density lipoprotein [oxLDL]; thiobarbituric acid reactive substances) and inflammatory (high-sensitive C-reactive protein [hs-CRP]) markers were evaluated. After consuming agraz, there was a tendency to increase the levels of antioxidants and to reduce the levels of hs-CRP in both genders. In addition, women who increased their serum phenols after consuming agraz had a significant reduction in insulin resistance, which was different from the results in men. Regarding men, those who increased their serum antioxidant capacity after consuming agraz had a better effect on the reduction of oxLDL levels that was significant compared to women. There are important differences between genders in the effects of agraz consumption in adults with MS. © Yeisson Galvis-Pérez et al., 2020; Published by Mary Ann Liebert, Inc.Entities:
Keywords: agraz; antioxidants; inflammation; insulin resistance; metabolic syndrome; oxidative stress
Year: 2020 PMID: 33269114 PMCID: PMC7703308 DOI: 10.1089/biores.2020.0053
Source DB: PubMed Journal: Biores Open Access ISSN: 2164-7844
Effects of Agraz on Metabolic Syndrome Components According to Gender
| Parameters | | Men | Women | p[ | p[ | p[ | ||
|---|---|---|---|---|---|---|---|---|
| Treatment | Baseline | Final | Baseline | Final | ||||
| WC (cm) | Placebo | 106 ± 1.6 | 106 ± 1.8 | 102 ± 1.8 | 102 ± 1.9 | 0.491 | 0.828 | 0.911 |
| Agraz | 107 ± 1.7 | 106 ± 1.7 | 102 ± 1.8 | 102 ± 1.9 | ||||
| SBP (mmHg) | Placebo | 124 ± 2.1 | 123 ± 1.9 | 118 ± 2.6 | 115 ± 2.5 | 0.017[ | 0.982 | 0.629 |
| Agraz | 124 ± 2 | 123 ± 1.8 | 118 ± 2.5 | 116 ± 2.3 | ||||
| DBP (mmHg) | Placebo | 76 ± 1.5 | 75 ± 1.3 | 76 ± 1.7 | 75 ± 1.6 | 0.001[ | 0.605 | 0.418 |
| Agraz | 77 ± 1.7 | 75 ± 1.3 | 76 ± 1.7 | 75 ± 1.7 | ||||
| Triglycerides (mg/dL) | Placebo | 240 ± 16 | 235 ± 14 | 204 ± 15 | 189 ± 10 | 0.379 | 0.574 | 0.884 |
| Agraz | 237 ± 15 | 231 ± 16 | 209 ± 19 | 203 ± 17 | ||||
| Glucose (mg/dL) | Placebo | 98 ± 1.5 | 97 ± 1.2 | 93 ± 1.2 | 96 ± 1.7 | 0.049[ | 0.994 | 0.058 |
| Agraz | 96 ± 1.5 | 98 ± 1.6 | 96 ± 1.6 | 96 ± 1.7 | ||||
| HDL-c (mg/dL) | Placebo | 37 ± 1.2 | 39 ± 1.0 | 41 ± 1.1 | 41 ± 1.1 | 0.034[ | 0.927 | 0.613 |
| Agraz | 37 ± 0.9 | 38 ± 1.2 | 41 ± 1.2 | 41 ± 1.3 | ||||
ANOVA of repeated measurements with multiple comparison Bonferroni test.
Significance <0.05.
Time.
Interaction time × treatment.
Interaction time × treatment × gender.
ANOVA, analysis of variance; DBP, diastolic blood pressure; HDL-c, high-density lipoprotein cholesterol; SBP, systolic blood pressure; WC, waist circumference.
Effects of Agraz on Antioxidant Capacity and Oxidative and Inflammatory Markers in Men and Women with Metabolic Syndrome
| Men | Women | p[ | p[ | |||
|---|---|---|---|---|---|---|
| Placebo | Agraz | Placebo | Agraz | |||
| Phenols (mg AG/L) | 235 ± 7 | 239 ± 6 | 313 ± 13 | 328 ± 7 | 0.327 | 0.586 |
| FRAP (μM Trolox/L) | 696 ± 19 | 696 ± 21 | 632 ± 17 | 640 ± 26 | 0.955 | 0.943 |
| NFκB (abs) | 0.12 ± 0.0 | 0.12 ± 0.0 | 0.11 ± 0.0 | 0.11 ± 0.0 | 0.954 | 0.154 |
| Insulin (mUI/L) | 27 ± 2 | 25 ± 2.3 | 21 ± 1.9 | 19 ± 1.7 | 0.432 | 0.974 |
| HOMA-IR | 6.7 ± 2.9 | 6.6 ± 2.9 | 5 ± 2.4 | 4.6 ± 2 | 0.752 | 0.646 |
| hs-CRP (mg/L) | 3.7 ± 0.2 | 3.3 ± 0.2 | 4.5 ± 0.4 | 3.8 ± 0.3 | 0.108 | 0.505 |
| TBARS (μM MDA) | 1.2 ± 0.08 | 1.2 ± 0.07 | 0.8 ± 0.06 | 0.8 ± 0.07 | 0.408 | 0.207 |
| oxLDL (ng/mL MDA) | 341 ± 33 | 306 ± 32 | 331 ± 23 | 332 ± 23 | 0.652 | 0.376 |
Two-way ANOVA with multiple comparison for Bonferroni test.
Treatment.
Interaction treatment × gender.
FRAP, ferric reducing antioxidant power; HOMA-IR, homeostatic model assessment of insulin resistance; MDA, malondialdehyde; oxLDL, oxidized low-density lipoprotein; TBARS, thiobarbituric acid reactive substances.
FIG. 1.Comparative effects of agraz consumption on insulin resistance between participants who increased versus those with no increase in their phenol content and by gender in both conditions. Two-way ANOVA with diet consumption correction. *p < 0.05; **p < 0.01. ANOVA, analysis of variance; HOMA-IR, homeostatic model assessment of insulin resistance.
FIG. 2.Comparative effects of agraz consumption on oxLDL concentrations between participants who increased versus not increased their antioxidant capacity (measured by FRAP) and by gender in both conditions. Two-way ANOVA with diet consumption correction. *p < 0.05; **p < 0.001. FRAP, ferric reducing antioxidant power; oxLDL, oxidized low-density lipoprotein.